



# TITAN BIOTECH LTD.

AN ISO 9001:2015 CERTIFIED COMPANY



Office : 903-909, 9<sup>th</sup> Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India  
Tel. : 011-27355742, 71239900 (44 Lines) | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

To,

13-02-2025

Corporate Services Department,  
BSE Ltd.,  
Phiroze Jeejeebhoy Tower,  
Dalal Street,  
Mumbai- 400001

Dear Sir,

**Sub: Sub: Integrated Filing (Financial) for the Quarter ended December 31, 2024**

**Ref: SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 Dated December 31, 2024**

Please find attached herewith the Integrated Filing (Financial) of Titan Biotech Limited for the quarter and nine months ended December 31, 2024.


Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 Dated December 31, 2024, read with Circular No. 20250102-4 issued by BSE Limited dated January 2, 2025.

The above information will be available on the website of the Company i.e <https://titanbiotechltd.com>

This is for your kind information and record please.

Thanking You,

**For Titan Biotech Limited**



**Charanjit Singh**  
**Company Secretary & Compliance Officer**  
M. No A12726  
As Enclosed

---

**R.O. & Works:** Unit I: A-902A, RIICO Industrial Aea, Phase III, Bhiwadi-301019, Rajasthan

**Unit II:** E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan

**E-mail:** hrd@titanbiotechltd.com,accounts@titanbiotechltd.com,,purchase@titanbiotechltd.com

**Website:** www.titanbiotechltd.com | www.tmmedia.in



# TITAN BIOTECH LTD.

AN ISO 9001:2015 CERTIFIED COMPANY



Office : 903-909, 9<sup>th</sup> Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India  
Tel. : 011-27355742, 71239900 (44 Lines) | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

## INTEGRATED FILING (FINANCIAL) FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2024

### A. FINANCIAL RESULTS

Attached as Annexure-A

### B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.

Not Applicable.

### C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES

Not Applicable.

### D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2<sup>nd</sup> and 4<sup>th</sup> Quarter)

Not Applicable for this Quarter ended on 31<sup>st</sup> December, 2024.

### E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4<sup>th</sup> Quarter)

Not Applicable for this Quarter ended on 31<sup>st</sup> December, 2024.

# Annexure-A

## TITAN BIOTECH LIMITED

Regd. Office :- A-902 A, RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com, www.titanbiotechltd.com, CIN : L74999RJ1992PLC013387

### STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31ST DECEMBER, 2024

(Rs. IN LAKHS) except for EPS

Sr. No	PARTICULARS	STANDALONE					
		QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED	
1	<b>INCOME</b>						
	Revenue from operations	3,827.58	3,989.11	4,597.89	12,128.15	12,415.34	16,407.21
	Other Income	158.95	31.86	43.70	253.18	127.10	174.82
	<b>Total Income</b>	<b>3,986.53</b>	<b>4,020.97</b>	<b>4,641.59</b>	<b>12,381.33</b>	<b>12,542.44</b>	<b>16,582.03</b>
2	<b>EXPENSES</b>						
	Cost of Materials Consumed	1,963.82	1,619.24	2,028.23	5,817.64	5,964.57	8,089.24
	Changes in inventories of Finished Goods, Stock-in-Trade and Work-in-Progress	(130.08)	131.86	124.98	(56.09)	(232.56)	(528.63)
	Employee Benefits Expense	666.61	649.90	602.34	1,943.57	1,690.68	2,371.06
	Finance Costs	14.85	26.55	26.37	72.30	82.92	117.00
	Depreciation and Amortization Expense	118.28	109.64	83.48	332.65	249.06	333.06
	Other Expenses	842.56	812.09	782.14	2,337.38	2,272.35	3,047.40
	<b>Total Expenses</b>	<b>3,476.04</b>	<b>3,349.28</b>	<b>3,647.54</b>	<b>10,447.45</b>	<b>10,027.02</b>	<b>13,429.13</b>
3	Profit before exceptional items and tax (1-2)	510.49	671.69	994.05	1,933.88	2,515.42	3,152.90
4	Exceptional Items	-	-	-	-	-	-
5	Profit before tax (3+4)	510.49	671.69	994.05	1,933.88	2,515.42	3,152.90
6	Tax expense:						
	(I) Current Tax	127.56	162.95	254.23	472.24	631.53	778.87
	(II) Deferred Tax	2.74	8.09	1.47	10.84	4.59	10.61
	(III) Earlier year taxes	-	0.30	-	0.30	(2.90)	(2.90)
	<b>Total Tax (I+II+III)</b>	<b>130.30</b>	<b>171.34</b>	<b>255.70</b>	<b>483.38</b>	<b>633.22</b>	<b>786.58</b>
7	Profit for the period (5-6)	<b>380.19</b>	<b>500.35</b>	<b>738.35</b>	<b>1,450.50</b>	<b>1,882.20</b>	<b>2,366.32</b>
8	<b>Other comprehensive income</b>						
	(i) Items that will not be reclassified to profit or loss						
A.	(ia) Re-measurement gain on defined benefit plans	5.84	5.84	2.07	17.52	6.23	23.36
	(ii) Income tax relating to these items	(1.47)	(1.47)	(0.52)	(4.41)	(1.57)	(5.88)
B.	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to these items	-	-	-	-	-	-
	<b>Total Other Comprehensive Income for the period (A+B) (net of taxes)</b>	<b>4.37</b>	<b>4.37</b>	<b>1.55</b>	<b>13.11</b>	<b>4.66</b>	<b>17.48</b>
9	<b>Total Comprehensive Income for the period (7+8)</b>	<b>384.56</b>	<b>504.72</b>	<b>739.90</b>	<b>1,463.61</b>	<b>1,886.86</b>	<b>2,383.80</b>
10	Paid-up equity share capital (Face Value of Rs. 10/- each)	826.37	826.37	826.37	826.37	826.37	826.37
11	Other Equity						12,017.85
12	Earnings per equity share (face value of Rs.10/- each) not annualised						
	(1) Basic	4.60	6.05	8.93	17.55	22.78	28.64
	(2) Diluted	4.60	6.05	8.93	17.55	22.78	28.64


#### Notes:

- The above standalone unaudited financial results for the quarter and nine months ended on 31.12.2024 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on February 12, 2025. The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements), 2015. The results for the quarter and nine months ended on 31st Dec. 2024, are available on the BSE Limited website(www.bseindia.com) and on the company's Website(www.titanbiotechltd.com)
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and nine months ended on 31st Dec. 2024 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The standalone unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operations for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

Place : Delhi  
Dated : 12.02.2025

For and on behalf of Board of Directors  
for TITAN BIOTECH LIMITED

[Naresh Kumar Singh]  
Managing Director  
DIN-00027448





**TITAN BIOTECH LIMITED**

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com, www.titanbiotechltd.com, CIN : L74999RJ1992PLC013387

**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31ST DECEMBER, 2024**

(Rs. IN LAKHS) except for EPS


Sr. No.	PARTICULARS	STANDALONE					
		QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED	
1	Total Income from Operations (Net)	3,986.53	4,020.97	4,641.59	12,381.33	12,542.44	16,582.03
2	Net Profit for the period (before tax, exceptional and/or extraordinary items)	510.49	671.69	994.05	1,933.88	2,515.42	3,152.90
3	Net Profit for the period before tax (after exceptional and/or extraordinary items)	510.49	671.69	994.05	1,933.88	2,515.42	3,152.90
4	Net Profit for the period after tax (after exceptional and/or extraordinary items)	380.19	500.35	738.35	1,450.50	1,882.20	2,366.32
5	Total comprehensive income for the period (comprising Profit for the period(after tax) and Other Comprehensive income(after tax)(refer note 3)	384.56	504.72	739.90	1,463.61	1,886.86	2,383.80
6	Paid-up Equity Share Capital ( Face value of Rs. 10/- per share)	826.37	826.37	826.37	826.37	826.37	826.37
7	Other Equity excluding Revaluation Reserves as per the balance sheet	-	-	-	-	-	12,017.85
8	Earnings Per Share (of INR 10/- each)						
	(a) Basic	4.60	6.05	8.93	17.55	22.78	28.64
	(b) Diluted	4.60	6.05	8.93	17.55	22.78	28.64

**NOTES :**

- The above is an extract of the detailed format of standalone unaudited Financial Results for the quarter and nine months ended on 31.12.2024 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements ) Regulations, 2015. The full format of the Standalone unaudited Financial Results for the said quarter and nine months ended on 31.12.2024 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com.
- The above standalone unaudited financial results for the quarter and nine months ended on 31.12.2024 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on February 12, 2025. The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements), 2015.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and nine months ended on 31.12.2024 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The standalone unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operations for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors  
for TITAN BIOTECH LIMITED

[Naresh Kumar Singla]  
Managing Director  
DIN-00027448



Place - Delhi  
Dated 12.02.2025



TITAN BIOTECH LIMITED

Regd. Office :- A-902 A, RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com, www.titanbiotechltd.com, CIN : L74999RJ1992PLC013387

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31ST DECEMBER, 2024

(Rs. IN LAKHS) except for EPS


Sr. No	PARTICULARS	CONSOLIDATED					
		QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED	
1	<b>INCOME</b>						
	Revenue from operations	3,827.58	3,989.11	4,597.89	12,128.15	12,415.34	16,407.21
	Other Income	158.95	31.86	43.70	253.18	127.10	174.82
	<b>Total Income</b>	<b>3,986.53</b>	<b>4,020.97</b>	<b>4,641.59</b>	<b>12,381.33</b>	<b>12,542.44</b>	<b>16,582.03</b>
2	<b>EXPENSES</b>						
	Cost of Materials Consumed	1,963.82	1,619.24	2,028.23	5,817.64	5,964.57	8,089.24
	Changes in Inventories of Finished Goods, Stock-in-Trade and Work-in-Progress	(130.08)	131.86	124.98	(56.09)	(232.56)	(528.63)
	Employee Benefit Expense	666.61	649.90	602.34	1,943.57	1,690.68	2,371.06
	Finance Costs	14.85	26.55	26.37	72.30	82.92	117.00
	Depreciation and Amortization Expense	118.28	109.64	83.48	332.65	249.06	333.06
	Other Expenses	842.56	812.09	782.14	2,337.38	2,272.35	3,047.40
	<b>Total Expenses</b>	<b>3,476.04</b>	<b>3,349.28</b>	<b>3,647.54</b>	<b>10,447.45</b>	<b>10,027.02</b>	<b>13,429.13</b>
3	Profit before exceptional items and tax (1-2)	510.49	671.69	994.05	1,933.88	2,515.42	3,152.90
4	Exceptional Items	-	-	-	-	-	-
5	Profit before tax (3+4)	510.49	671.69	994.05	1,933.88	2,515.42	3,152.90
6	Tax expense:						
	(I) Current Tax	127.56	162.95	254.23	472.24	631.53	778.87
	(III) Deferred Tax	2.74	8.09	1.47	10.84	4.59	10.61
	(II) Earlier year taxes	-	0.30	-	0.30	(2.90)	(2.90)
	<b>Total Tax (I+II+III)</b>	<b>130.30</b>	<b>171.34</b>	<b>255.70</b>	<b>483.38</b>	<b>633.22</b>	<b>786.58</b>
7	Profit for the period (5-6)	380.19	500.35	738.35	1,450.50	1,882.20	2,366.32
8	Share in Profit of Associate	58.82	169.16	(20.88)	297.98	103.47	118.98
9	<b>Profit for the period (7+8)</b>	<b>439.01</b>	<b>669.51</b>	<b>717.47</b>	<b>1,748.48</b>	<b>1,985.67</b>	<b>2,485.30</b>
10	Other comprehensive income						
	(i) Items that will not be reclassified to profit or loss						
A.	(ia) Re-measurement gain on defined benefit plans	5.84	5.84	2.07	17.52	6.23	23.36
	(ii) Income tax relating to these items	(1.47)	(1.47)	(0.52)	(4.41)	(1.57)	(5.88)
B	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to these items	-	-	-	-	-	-
	<b>Total Other Comprehensive Income for the period (A+B) (net of taxes)</b>	<b>4.37</b>	<b>4.37</b>	<b>1.55</b>	<b>13.11</b>	<b>4.66</b>	<b>17.48</b>
11	<b>Total Comprehensive Income for the period (7+8)</b>	<b>443.38</b>	<b>673.88</b>	<b>719.02</b>	<b>1,761.59</b>	<b>1,990.33</b>	<b>2,502.78</b>
12	Net profit attributable to:						
	Owners of the holding company						
	Non-controlling interest						
13	Other comprehensive income attributable to :						
	Owners of the holding company						
	Non-controlling interest						
14	<b>Total Comprehensive Income attributable to (10+11)</b>						
	Owners of the holding company						
	Non-controlling interest						
15	Paid-up equity share capital (Face Value of Rs. 10/- each)	826.37	826.37	826.37	826.37	826.37	826.37
16	Other Equity						12,518.75
17	Earnings per equity share (face value of Rs.10/- each) not annualised						
	(1) Basic	5.31	8.10	8.68	21.16	24.03	30.07
	(2) Diluted	5.31	8.10	8.68	21.16	24.03	30.07

Notes:

- The above consolidated unaudited financial results for the quarter and nine months ended on 31.12.2024 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on February 12, 2025. The statutory auditors of the company have carried out a limited review of the aforesaid results. The results for the quarter and nine months ended Dec. 31, 2024, are available on the BSE Limited website(www.bseindia.com) and on the company's Website(www.titanbiotechltd.com)
- The consolidated unaudited financial results for the quarter and nine months ended on 31.12.2024 include the results of following:-  
Associate Companies - Peptech Biosciences Limited and Titan Media Limited
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and nine months ended Dec. 31, 2024 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The consolidated unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operations for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors  
for TITAN BIOTECH LIMITED

[Naresh Kumar Singla]  
Managing Director  
DIN-00027448



Place : Delhi  
Dated : 12.02.2025



TITAN BIOTECH LIMITED

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com, www.titanbiotechltd.com, CIN : L74999RJ1992PLC013387

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31ST DECEMBER, 2024

(Rs. IN LAKHS) except for EPS


Sr. No	PARTICULARS	CONSOLIDATED					
		QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED	
1	Total Income from Operations (Net)	3,986.53	4,020.97	4,641.59	12,381.33	12,542.44	16,582.03
2	Net Profit for the period (before tax, exceptional and/or extraordinary items)	510.49	671.69	994.05	1,933.88	2,515.42	3,152.90
3	Net Profit for the period before tax (after exceptional and/or extraordinary items)	510.49	671.69	994.05	1,933.88	2,515.42	3,152.90
4	Net Profit for the period after tax (after exceptional and/or extraordinary items)	439.01	669.51	717.47	1,748.48	1,985.67	2,485.30
5	Total comprehensive income for the period (comprising Profit for the period(after tax) and Other Comprehensive income(after tax)(refer note 3)	443.38	673.88	719.02	1,761.59	1,990.33	2,502.78
6	Paid-up Equity Share Capital ( Face value of Rs. 10/- per share)	826.37	826.37	826.37	826.37	826.37	826.37
7	Other Equity excluding Revaluation Reserves as per the balance sheet	-	-	-	-	-	12,518.75
8	Earnings Per Share (of INR 10/- each)						
	(a) Basic	5.31	8.10	8.68	21.16	24.03	30.07
	(b) Diluted	5.31	8.10	8.68	21.16	24.03	30.07

NOTES :

- The above is an extract of the detailed format of consolidated unaudited Financial Results for the quarter and nine months ended on 31.12.2024 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the consolidated unaudited Financial Results for the said quarter and nine months ended on 31st December 2024 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com.
- The above consolidated unaudited financial results for the quarter and nine months ended on 31.12.2024 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on February 12, 2024. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and nine months ended on 31.12.2024 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The consolidated unaudited financial results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operations for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors  
for TITAN BIOTECH LIMITED

[Naresh Kumar Singla]  
Managing Director  
DIN-00027448



Place : Delhi  
Dated : 12.02.2025



# **A N S K & Associates**

**CHARTERED ACCOUNTANTS**

**OFFICE : 705, B-08, GDITL Tower, Netaji Subhash Place,  
Pitampura, New Delhi-110034**

**OFFICE NO. 011-46010089**

**EMAIL :amccorporateservices@gmail.com**

---

---

## **Independent Auditor's Review Report on Quarterly and year to date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

To,

THE BOARD OF DIRECTORS  
TITAN BIOTECH LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of Titan Biotech Limited (the "Company"), for the quarter ended December 31, 2024 and the year to date results for the period 1<sup>st</sup> April 2024 to 31<sup>st</sup> December 2024 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



# A N S K & Associates

CHARTERED ACCOUNTANTS

OFFICE : 705, B-08, GDITL Tower, Netaji Subhash Place,  
Pitampura, New Delhi-110034

OFFICE NO. 011-46010089

EMAIL :amccorporateservices@gmail.com

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

## For A N S K & Associates

Chartered Accountants

Firm's Registration No. 026177N

AKHIL  
MITTAL

Digitally signed by AKHIL MITTAL  
DN: cn=AKHIL MITTAL, o=CA, ou=CA, email=AKHIL.MITTAL@ANSKCA.COM, c=IN  
c=IN, cn=AKHIL MITTAL, o=CA, ou=CA, email=AKHIL.MITTAL@ANSKCA.COM, c=IN  
AKHIL MITTAL, Chartered Accountant, Firm's Registration No. 026177N  
Date: 2025.02.12 12:27:14 +05'30'

(CA Akhil Mittal)

Partner

M.No. 517856

Date: 12.02.2025

Place: New Delhi

UDIN: 25517856BMKXIG1757





# **A N S K & Associates**

**CHARTERED ACCOUNTANTS**

**OFFICE : 705, B-08, GDITL Tower, Netaji Subhash Place,  
Pitampura, New Delhi-110034**

**OFFICE NO. 011-46010089**

**EMAIL :amccorporateservices@gmail.com**

---

---

## **Independent Auditor's Review Report on Quarterly and Year to date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

To,

THE BOARD OF DIRECTORS  
TITAN BIOTECH LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Titan Biotech Limited (the "Company") and its Associates, for the quarter ended December 31, 2024 and the consolidated year to date results for the period from 1 April 2024 to 31 December 2024 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

